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Abstract
Background:  The development of breast cancer is multifactorial. Hormonal, environmental
factors and genetic predisposition, among others, could interact in the presentation of breast
carcinoma. Human leukocyte antigen (HLA) alleles play an important role in immunity (cellular
immunity) and may be important genetic traits. HLAAllele-specific interaction has not been well
established. Recently, several studies had been conducted in order to do so, but the results are
controversial and in some instances contradictory.
Methods: We designed a case-control study to quantify the association of HLA class I and II genes
and breast cancer. HLA typing was performed by high resolution sequence-specific oligotyping after
DNA amplification (PCR-SSOP) of 100 breast cancer Mexican mestizo patients and 99 matched
healthy controls.
Results: HLA-A frequencies that we were able to observe that there was no difference between
both groups from the statistical viewpoint. HLA-B*1501 was found three times more common in
the case group (OR, 3.714; p = 0.031). HLA-Cw is not a marker neither for risk, nor protection
for the disease, because we did not find significant statistical differences between the two groups.
DRB1*1301, which is expressed in seven cases and in only one control, observing an risk increase
of up to seven times and DRB1*1602, which behaves similarly in being present solely in the cases
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(OR, 16.701; 95% CI, 0.947 – 294.670). DQ*0301-allele expression, which is much more common
in the control group and could be protective for the presentation of the disease (OR, 0.078; 95%
CI, 0.027–0.223, p = 0.00001).
Conclusion: Our results reveal the role of the MHC genes in the pathophysiology of breast
cancer, suggesting that in the development of breast cancer exists a disorder of immune regulation.
The triggering factor seems to be restricted to certain ethnic groups and certain geographical
regions since the relevant MHC alleles are highly diverse. This is the first study in Mexican
population where high resolutions HLA typing has been performed in order to try to establish an
association with malignancy.
Background
Breast cancer is a common neoplasm around the world
with almost 1 million cases diagnosed every year, it is also
considered the most frequent malignant neoplasm in
developed countries, globally accounts for 18% of all
female cancers [1]. In Mexico, this neoplasm occupies sec-
ond place, preceded only by cancer of the cervix, which
occupies 10.6% of all tumors and 16.4% of all tumors in
women. It is considered that the combination of cervico-
uterine cancer and breast cancer corresponds to 49% of all
neoplasms in Mexican women [2].
Multiple factors are associated with an increase in breast
cancer development, including age, family history, expo-
sure to hormones (endo – as well as exogenous), diet,
benign mammary disease, and environmental and genetic
factors. The majority of these factors moderately increase
the risk of developing cancer. It is estimated that at least
50 and up to 80% of women who develop breast cancer
do not possess predisposing factors in addition to gender
and age [3].
According to Rodríguez-Cuevas et al. [4], in Mexico from
1993 – 1995, 29,075 new cases of breast cancer were
reported, of which 45.5% presented at the age of < 50
years; it is noteworthy that the most affected age group
was that of 40 – 49 years, corresponding to 29.5% of all
tumors. When a comparison was carried out with studies
reported by other authors, it was found that in Mexico,
this disease presented at least one decade prior to presen-
tation in European countries or in the U.S. On conducting
a comparative evaluation with other Latin American
countries such as Venezuela [5], we found that the per-
centage of women < 50 years of age with a diagnosis of
breast cancer is similar to that of Mexico. Thus, we con-
cluded that Latin American women have the tendency to
develop this type of neoplasm at an earlier age [4,5].
This observation is similar to that for Japanese women, in
whom 46.5% of women with this disease were aged < 50
years [6]. It appears that environmental or dietary factors
are not responsible for this behavior, because reports in
the literature evaluating Hispanic patients residing in Los
Angeles, California, or in the U.S. state of New Mexico
show a percentage of presentation (38 – 39%) similar to
that of ages of women living in Mexico or other Latin
American countries [7]. According to this information, it
is possible that there is (are) some factor(s) that make(s)
women present this disease when no other risk factor is
found.
One of the predisposing factors can be genes located
within the major histocompatibility complex (MHC)
region; the association between human leukocyte antigen
(HLA) gene products with a disease does not necessarily
reflect the direct involvement of these molecules in the
disease process [8], and because many genes can be in
linkage disequilibrium with other MHC genes, this possi-
ble association could be due solely to a closely associated
gene.
The HLA system involvement in the development of can-
cer is poorly understood; nonetheless, it is widely recog-
nized that MHC genetic variations lead to greater
susceptibility to neoplasm development [9]. Neoplastic
cells express a number of genes not expressed by their nor-
mal counterpart, and also some peptides of some proteic
products of these HLA molecule-associated genes [10].
The role of oncogene – and tumor suppressor gene-
acquired changes is widely recognized; similarly, there is
growing evidence suggesting that the immune system
plays a protector role in tumorigenesis [11,12]. In patients
with cancer, HLA peptide complex-stimulated T-cell
responses are not sufficiently effective for eliminating
tumor cells. Loss of HLA expression or deregulation has
been reported in a great variety of tumors, including
breast cancer [13]; changes in the expression of these anti-
gens have been associated with poor prognosis. Notwith-
standing this, in tumoral tissue class I antigen expression
is rarely lost in its entirety [14]. Such changes connote the
possibility that this represents mechanisms by which neo-
plastic cells escape cell-mediated immunological surveil-
lance – due to their being poor targets for cytotoxic T-cells
– allowing for tumor dissemination and metastasis [15].BMC Cancer 2009, 9:48 http://www.biomedcentral.com/1471-2407/9/48
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If immunological surveillance is important during tumor-
igenesis, certain individuals who inherit specific HLA class
I alleles, which are highly polymorphic, such as DRB or
DQB, can be more susceptible to developing tumors, or
contrariwise, more resistant to the growth of these
[13,14].
In breast cancer, the study of HLA is reduced; the greatest
number of studies is conducted on HLA class I expression.
These studies have shown that up to 80% of tumors
exhibit partial or total loss of HLA class I antigens [16,17],
while other tumors such as cervix, larynx, melanoma,
colon, and pancreas demonstrate a loss of up to 40 – 50%
[18-20]. Evaluation has arrived at the field of prognosis;
for example, in the study of Gudmundsdottir et al. [21],
the authors showed that a cohort of 187 patients with
clinical stages I and II, mixed HLA class I expression exhib-
ited an increase in the probability of late recurrence and a
greater probability of death (odds ratio [OR] = 3.42; p =
0.014) due to the disease in patients with negative auxil-
iary lymph nodes in comparison with patients demon-
strating total negativity or positivity, especially after 5
years.
The first evaluation of HLA class II and their alleles was
carried out by Chaudhuri et al. [13] in a group of 173
patient with breast cancer and 215 Caucasian-origin con-
trols, showing the presence of the DRB3*0201/*0202
allele in 55% of cases and in 40.9% of controls (p  =
0.0072) as risk factor. At the same time, the authors con-
cluded that DQB*03032 and DRB1*11 alleles represent
resistance factors toward the disease. HLA polymorphisms
appear to be responsible for the immune response varia-
tions in different individuals to different antigens and can
contribute to susceptibility to the disease, specifically to
non virus-related tumors, because breast cancer frequency
in Mexico is high, thus considered a health problem, and
the disease is present in any age group, with the character-
istic of presenting at an earlier age than in other countries,
and with the evidence that between 50 and 80% [1,3] of
patients do not present the classical risk factors of the dis-
ease; therefore, it is necessary to investigate whether there
is loss of control of the immune system regarding the
tumor cell in this group of sick persons that allows neo-
plastic growth. At present, there are no reports of HLA sys-
tem alleles in Mexican mestizo female population with
breast cancer.
Methods
Subjects
We developed a case-control study at the National Insti-
tute of Cancerology (Instiuto Nacional de Cancerología
de México, INCan) in Mexico City. A case was defined as
a Mexican mestizo female patient with at least two previ-
ous generations born in Mexico, in whom breast cancer
confirmed by histopathology has been diagnosed, who
has been treated at the INCan Breast Tumor Service. A
control was defined as a Mexican mestizo female patient
who has at least two previous generations born in Mexico,
from open population, without a family history of any
type of cancer, with emphasis placed on breast, colon,
ovary, and prostate cancer, without a history of autoim-
mune diseases, who has been submitted to breast and/or
radiological exploration that discard pathology at this
level according to patient age. We applied a clinical his-
tory oriented toward determination of personal and
familial antecedents-of-interest; in the case of obtaining
no response being or the response being positive, the
patient was excluded from the study.
Determination of the absence of mammary pathology was
performed according to patient age, with the following
American Cancer Society (ACS) guidelines for detection of
early breast cancer [22]: a) In women < 40 years of age, a
clinical examination was conducted exclusively; in the
case of requiring further evaluation, the patient was dis-
carded as a control and excluded from the study, and b) in
women aged > 40 years, we carried out a clinical examina-
tion as well as a mammographic study and breast ultra-
sound (US) to determine mammary pathology. In the
case of obtaining an abnormal result or requiring further
examination, the patient was discarded as a control.
The study was evaluated and approved by the Scientific
and Ethical Committee of the Instituto Nacional de Can-
cerología de México, and all patients who were evaluated
provided informed consent for radiographic studies, the
taking of blood samples, and evaluation of genetic mate-
rial. This study was performed in collaboration and with
the technical and methodological support of the Ameri-
can Red Cross in Nedham Massachusetts, USA.
HLA typing
Genomic DNA was obtained from peripheral blood leu-
kocytes and extracted by standard techniques [23,24].
Amplification of genomic DNA
HLA-DQA1 and – DQB1 typing were amplified by PCR
and hybridized to sequence specific oligonucleotide
probes. Primers used for HLA-DQ amplification included
DQAAMP-A,-B, DQBAMP-A, and -B. These were synthe-
sized in a DNA-SM automated synthesizer (Beckman,
Palo Alto, CA, USA). These typing techniques were
approved by the 12th International Histocompatibility
Workshop.
Dot blot hybridization
Five percent of the amplified DNA was denatured in 0.4
mol/L NaOH for 10 min, neutralized in 1 mol/L of
ammonium acetate, and transferred to a Hybond-N mem-BMC Cancer 2009, 9:48 http://www.biomedcentral.com/1471-2407/9/48
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brane (Amersham, Bucks, UK). The filters were prehybrid-
ized at 42°C for 30 min in a solution containing 6× SSPE
(30× SSPE: 4.5 mol/L NaCl, 0.3 mol/L NaH2PO4, 30
mmol/L EDTA, pH = 7.4), 5× Denhard solution (2%
bovine serum albumin, 2% polyvinylpyrrolidone 40, 2%
Ficoll 400), 0.1% Lauryl-sarcosine, and 0.02% SDS. Then,
the oligonucleotide probes labeled with Digoxygenin
dideoxy- Uridine-Triphosphate (Dig-11-ddUTP) were
added and hybridized at 42°C for 3 h. The filters were
washed twice in 2× SSPE, 0.1% SDS at room temperature
for 10 min, once in TMAC solution [50 mmol/L Tris-HCl
(pH = 8.0), 3 mol/L tetramethylammonium chloride, 2
mmol/L EDTA, 0.1% SDS] at room temperature for 10
min, and twice at 60°C for 10 min. Dots were revealed
using the Dig Nucleic Acid Detection Kit (Boehringer
Mannheim Biochemical, Mannheim, Germany).
Statistical analysis
HLA-A, HLA-B, HLA-C, allele and haplotype frequencies
were estimated using the Arlequin program version 2.000
[25]. Significance of two-locus linkage disequilibrium
(LD) was determined using Popgene program version
1.31 [26]. Odds ratio (OR) was calculated as per Haldane
modified Woolf's formula [27]. OR = [(a + 0.5) (d + 0.5)/
(b + 0.5) (c + 0.5)] where, a and b are the number of
patients and controls positive for a given allele respec-
tively, while c and d represent the number of patients and
controls negative for the allele, respectively. The corrected
P value was calculated using Bonferroni's inequality
method [28] as, P corrected = 1- (1-p)n, where n =
number of comparisons.
Association between HLA haplotype and breast cancer
was examined using statistical analysis from a 2 × 2 table
according to the method described by Svejgaard and
Ryder [29].
Results
During the study period, we included 100 patients who
fulfilled inclusion and exclusion criteria with a confirmed
diagnosis of breast cancer. Similarly, we obtained 99 sam-
ples of healthy control subjects.
Age of patients with breast cancer ranged from 27 – 82
years (average age, 50.4 ± 12.8 years); distribution was
normal. Seventy two cases did not present a familiar his-
tory of breast cancer, and in 28 cases, there was at least one
first-degree family member with this neoplasm type; aver-
age age at menarche was 12.8 years. Seventy one percent
of women used no family planning method, while use of
oral hormones or another hormonal-therapy type was
present only in 29 patients; the remainder of patients uti-
lized some other family planning method. History of
smoking as a risk factor was present in only 16% of
patients.
Locally advanced and advanced clinical stages were the
most frequent (64%) stages in comparison with early
stages. It is noteworthy that in 15% of cases, it was not
possible to determine the clinical stage because the
patients had been care for previously at another hospital.
It was possible to determine tumor size in 89 cases, with
an average of 5.2 cm (standard deviation [SD] ± 3.49;
range, 1 – 17 cm); in addition, it was possible to deter-
mine the distribution of clinical lymph node status in 94
patients, the most frequent lymph node status being N1
with 46 cases, and the second most frequent, N0 with 23
patients, according to the Tumor-Node-Metastasis (TNM)
lymph node staging description.
As expected due to neoplasm frequency, distribution by
histological type obtained 94 cases of infiltrating ductal
carcinoma and only six cases of infiltrating lobular carci-
noma. Concerning differentiation degree, we found
poorly differentiated carcinoma in 56% of cases, while
moderately and well differentiated presented in 38 and
6% of cases, respectively. Distribution of differentiation
degree with respect to the Scarff-Bloom-Richardson Index
exhibited the presence of high-grade tumors in 67% of
patients; the hormonal receptors of these tumors were dis-
tributed as follows: Positive estrogenic receptors in 54
cases; negative estrogenic receptors in 45 cases; positive
pregestational receptors in 29 cases, and negative preges-
tational receptors in 70 cases. In one case, it was not pos-
sible to conduct hormonal receptor determination.
Patient clinical characteristics were shown, as well as those
of the neoplasms in Table 1.
At the moment of performing the present study, 61
patients were found without evidence of disease, while 39
cases presented disease recurrence (data not shown, in
that this was not the objective of the present work).
Table 2 shows the different HLA classes I and II alleles
studied in the group of cases, as well as their genetic fre-
quencies. Table 3 depicts the different HLA classes I and II
alleles studied in the control group of patients, as well as
the genetic frequencies of these.
In Table 4, we found alleles with the highest genetic HLA-
A frequencies that were detected; we were able to observe
that there was no difference between both groups from
the statistical viewpoint, although we noted a tendency
for risk in one of these (*0206), as well as one for protec-
tion in the other (*6801), after correction for multiple
comparisons for the number of alleles of HLA-A locus (n
= 11), the risk was not significant (Pc = 0.45). It is worth-
while mentioning that the following four alleles were the
most frequent in both groups: HLA-A*0201; -*2402; -
*0206, and -*3101. In addition, also depicted in this
Table are high-resolution HLA-B typifications with great-BMC Cancer 2009, 9:48 http://www.biomedcentral.com/1471-2407/9/48
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est genetic frequency compared – if only one exhibited a
statistically significant difference for the risk factor, on
finding this with a three times greater frequency in the
case group in comparison with the control group HLA-
B*1501 (OR, 3.714; p = 0.031). After correction for mul-
tiple comparisons for the number of alleles of HLA-B
locus (n = 17), the risk was not significant (Pc = 0.30).
HLA-Cw is a scarcely studied gene in this neoplasm type;
we are able to say that at least in this group of women
obtained from an ethnically similar population, HLA-Cw
is not a marker for, nor a risk for, nor protection for the
disease, because we did not find differences between the
two groups.
In Table 5, we can observe HLA-DR distribution, in which
we are able to identify two alleles that on being expressed
comprise an associated risk factor for presenting the dis-
ease, such as DRB1*1301, which is expressed in seven
cases and in only one control, observing an risk increase
of up to seven times; notwithstanding this, it is important
to mention that the confidence interval (CI) is very broad,
which can be a reflection of its low genetic frequency
(genetic frequency [g.f.] = 0.040) and DRB1*1602, which
behaves similarly in being present solely in the cases (in
seven of these) (OR, 16.701; 95% CI, 0.947 – 294.670),
after correction for multiple comparisons for the number
of alleles of HLA-DRB1 locus (n = 11), the risk was not sig-
nificant (Pc = 0.24). Regarding HLA- DQ, we found two
alleles of this gene associated with the disease, such as
DQ*0302 with a g.f. of 0.454 in the group of cases, and a
g.f. of 0.274 in the control group (OR, 2.201;95%
CI,1.419–3.415), after correction for multiple compari-
sons for the number of alleles of HLA-DQ locus (n = 8),
the risk was statistically significant (Pc = 0.0007). How-
ever, the allele commanding the majority of attention is
DQ*0301-allele expression, which is much more com-
mon in the control group (g.f., of 0.231) being a protector
presentation of the disease. This relationship is sustained
after corrections for multiple comparisons (Pc = 0.00008)
for HLA-DQB1 (n = 8).
Haplotypes were deduced both the results are highly het-
erogenic (data not show) therefore not conclusions could
be drawn or associations performed.
Discussion
The origin of malignant neoplasms is multifactorial [1];
nevertheless, there are certain factors that can increase not
only the risk for appearance of the disease, but even more
so that the tumor would continue to grow and would pro-
duce distal disease or metastasis. Thus, if immunological
surveillance is an important mechanism in the tumor gen-
esis process, certain individuals who inherit specific HLA
class II alleles can be resistant or more susceptible to
tumor presentation [13]. The results of different works
show few reproducible results because there are important
differences in the expression of the different HLAs,
depending on the geographical area to which reference is
made [34]. This is due to that the frequency of presenta-
tion of the different HLA alleles is determined by the dom-
inant pathogens of each geographic region in particular,
and because these genes are highly polymorphic.
Breast cancer has exhibited an increase in incidence in
recent years, it is the tumor second only to lung cancer as
cause of death by cancer in females, and is the number
one cause of death by cancer in women 15 – 54 years of
age worldwide [31]. In Mexico, breast cancer is a very fre-
Table 1: Patient Clinical Characteristics and Neoplasm 
Characteristics
n
Age 50.4 +/- 12.8 (Mean +/- SD)
Menarche 12.8 (Median)
Family history Positive 28
Negative 72
Family planning Positive for hormonal 29
Negative 71
Tobbaco Positive 16
Clinical stage I 8
IIa 13
IIb 23
IIIa 19
IIIb 13
IV 9
No classified 15
Tumor size 5.2 +/- 3.49 (Mean +/- SD)
Nodal status N0 26
N1 46
N2 21
N3 1
Missing 6
Histology Ductal 94
Lobular 6
Grade Well differentiated 6
Moderately 38
Poorly 56
Hormone receptor status Estrogen positive 54
Estrogen negative 45
Progesterone positive 29
Progesterone negative 70BMC Cancer 2009, 9:48 http://www.biomedcentral.com/1471-2407/9/48
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quent tumor; thus, study of this disease and the factors
that predispose its presentation is of prime importance for
identification of at-risk groups, which translates into a
more precise evaluation for each woman [5].
To date, few studies have been conducted to attempt to
determine the association and impact that these represent
in the risk of presenting breast cancer and the different
HLA, especially HLA class II, and some studies lack suffi-
cient power due to a reduced number of studied cases
[33].
In 2005 Lavado et al. [34], compared 132 women with
breast cancer and 382 healthy controls in the Spanish
region of Málaga. They performed HLA-A,-B, -Cw, -DR,
and -DQ typification. The most important differences
were found in the HLA-B locus, where the HLA-B7 allele
was present with greater frequency in the group of sick
patients than in the control group (p = 0.0019; 95% CI,
1.337 – 3.409; Relative risk [RR], 2.135), explaining that
in this geographical zone an environmental agent can be
found (whether viral or bacterial) that can be associated
with breast cancer. Our study reveals a significantly
increased frequency of HLA-B*1501 in cancer patients in
comparison to healthy controls (OR = 3.714; CI95%,
1.187–11.619, p = 0.031) but not in other HLA-B alleles.
Gopalkrishnan et al. [36], in a group of women from
India, evaluated low- or intermediate-resolution gene
expression of HLA-A,-B, and -C, finding the following two
alleles as candidates for markers associated in risk modu-
lation for breast cancer in Eastern Indian women: Alleles
HLA-B*40 and -B*08, the first as a factor for early devel-
opment of the disease, presenting in 16% of cases vs.
9.0% of controls (OR, 2.2; 95% CI, 1.15 – 4.34; p = 0.02),
and the second, found to be a protector. These protective
or high risk alleles even though were frequent in our pop-
ulation (HLA-B*40 g.f.= 0.080 and -B*08 g.f. = 0.046)
associations were not statistically significant neither for
risk not for protection to the development of the neo-
plasm.
We found HLA-DQB1*0302 to be protective as well as
HLA-DQB1*0301 but not associated with age, which is
Table 2: Frequencies (g.f) of HLA-A,-B, Cw, DRB1 and – DQB1 in Cases.
-A n g.f -B n g.f -Cw n g.f -DRB1 n g.f -DQB1 n ggg.f g.f
0201 39 0.224 1501 13 0.074 0401 34 0.195 0802 27 0.155 0300 54 0.310
2402 25 0.143 3501 13 0.074 0702 29 0.167 0407 22 0.126 0302 30 0.172
0206 20 0.114 4002 11 0.063 0102 16 0.092 1406 14 0.080 0402 29 0.167
3101 16 0.091 5101 9 0.051 0701 13 0.075 0404 12 0.069 0200 18 0.103
6801 8 0.045 5201 9 0.051 0602 11 0.063 0301 12 0.069 0501 10 0.057
1101 8 0.045 3905 9 0.051 0303 9 0.052 0701 11 0.063 0602 6 0.034
6803 7 0.040 3512 8 0.046 0304 8 0.046 1301 7 0.040 0603 5 0.029
0101 7 0.040 0801 8 0.046 1203 7 0.040 1602 7 0.040 0601 5 0.029
0301 5 0.028 3517 7 0.040 1502 7 0.040 1501 6 0.034 0600 4 0.023
2601 5 0.028 3906 6 0.034 0801 6 0.034 0102 6 0.034 0303 4 0.023
3201 5 0.028 4801 6 0.034 0305 6 0.034 1402 5 0.029 0202 2 0.011
2902 5 0.028 0702 5 0.029 1509 5 0.029 0403 4 0.023 0503 2 0.011
3001 4 0.023 3801 5 0.029 1202 4 0.023 0410 4 0.023 0502 1 0.006
6802 3 0.017 4403 4 0.023 0802 4 0.023 1502 4 0.023 0201 1 0.006
2425 2 0.011 5001 4 0.023 1601 4 0.023 0402 3 0.017 0604 1 0.006
2501 2 0.011 1402 4 0.023 0202 3 0.017 1302 3 0.017
3301 2 0.011 3514 4 0.023 1604 2 0.011 1101 3 0.017
3010 1 0.005 4402 3 0.017 0803 2 0.011 0411 3 0.017
0302 1 0.005 1530 3 0.017 0509 1 0.005 0401 2 0.011
2301 1 0.005 1302 3 0.017 1801 1 0.005 0101 2 0.011
6805 1 0.005 3508 3 0.017 1701 1 0.005 1104 2 0.011
2201 1 0.005 4006 2 0.011 0501 1 0.005 1305 2 0.011
7401 1 0.005 3908 2 0.011 0405 2 0.011
3131 1 0.005 1515 2 0.011 1503 1 0.005
6901 1 0.005 4101 2 0.011 1601 1 0.005
3002 1 0.005 1801 2 0.011 1448 1 0.005
0205 1 0.005 4501 2 0.011 1404 1 0.005
2403 1 0.005 3503 2 0.011 1202 1 0.005
2705 2 0.011 0302 1 0.005
3905 2 0.011 0103 1 0.005
4008 1 0.005 1001 1 0.005
other 18 0.114 1401 1 0.005
N = 174.BMC Cancer 2009, 9:48 http://www.biomedcentral.com/1471-2407/9/48
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contrary to what was reported by Chaudhuri et al. [13] in
2000, where he reports two important negative associa-
tions for the development of breast cancer at an early age,
both of HLA class II: DRB*11, which was found expressed
in 35 controls and only in six cases (p < 0.0001). These
results reflect, at least in the patient group, that inherit-
ance of the alleles of these genes (DQB*03032 and
DRB1*11) represent alleles resistant to the presentation
of early-age breast cancer.
Positive association of specific HLA class II alleles in any
malignant-tumor type reflects the specific role of these
molecules in the promotion of chronic inflammation.
HLA expression suggests that immune-system evasion of
certain cellular populations could be responsible for pro-
moting survival of the neoplasm, thus rendering it neces-
sary to continue evaluating these markers in different
populations and to include greater numbers of patients to
confirm the different associations and risks between alle-
les and haplotypes and to determine whether there are
others that could be catalogued as risk factors for develop-
ment of the neoplasm, and at a determined moment
whether the fact that some allele, alleles, or haplotypes are
found expressed consistently in some group of individuals
affords the power to utilize HLA class II typifications as
prognostic factors, at the present moment few authors had
performed characterization of HLA in latin population,
we could say this is the first attempt to characterize a Mex-
ican mestizo population in order to try to find associa-
tions between HLA and breast cancer.
Conclusion
The results obtained by our group demonstrate the role of
genetics in the multifactorial pathophysiology of breast
malignant neoplasms. It also reveals the role of the MHC
genes in the pathophysiology, suggesting that in the
development of breast cancer exists a disorder of immune
regulation.
Nevertheless, this triggering factor (MHC genes) seems to
be restricted to certain ethnic groups as well as certain geo-
graphical regions since these relevant MHC alleles are
Table 3: Frequencies (g.f) of HLA-A,-B,-Cw,-DRB1 and – DQB1 in controls.
-A n g.f -B n g.f -Cw n g.f -DRB1 n g.f -DBQ1 n g.f
0201 41 0.220 3905 19 0.102 0702 40 0.215 0407 33 0.177 0302 51 0.274
2402 31 0.166 3512 14 0.075 0401 36 0.194 0802 25 0.134 0301 43 0.231
6801 19 0.102 4002 13 0.069 0304 16 0.086 0404 15 0.081 0402 28 0.151
3101 13 0.069 5101 11 0.059 0102 15 0.081 1406 15 0.081 Dqbx 21 0.113
AX 11 0.059 3501 11 0.059 Cwx 13 0.070 Drx 13 0.070 0501 12 0.065
0206 10 0.053 3906 10 0.053 0701 9 0.048 0701 12 0.065 0202 10 0.054
6803 8 0.03 BX 10 0.053 0602 8 0.043 1602 11 0.059 0201 6 0.032
3002 6 0.032 3514 6 0.032 0801 7 0.038 1501 7 0.038 0602 5 0.027
0301 6 0.032 4005 6 0.032 0802 7 0.038 1104 7 0.038 0603 3 0.016
3301 5 0.026 0702 6 0.032 0303 5 0.027 0301 6 0.032 0502 2 0.011
1101 4 0.021 4801 5 0.026 0501 4 0.022 0102 6 0.032 0303 2 0.011
0101 4 0.021 1402 5 0.026 1502 4 0.022 1402 5 0.027 0604 1 0.005
6802 4 0.021 5201 4 0.021 0305 3 0.016 0403 4 0.022 0601 1 0.005
2301 3 0.016 3543 4 0.021 1203 3 0.016 0101 3 0.016 0304 1 0.005
2601 3 0.016 0801 4 0.021 0202 3 0.016 0401 3 0.016
2902 3 0.016 1501 4 0.021 0306 3 0.016 1001 3 0.016
3201 3 0.016 3517 3 0.016 1601 2 0.010 0804 2 0.010
6805 2 0.010 1515 3 0.016 1402 2 0.010 0411 2 0.010
3001 2 0.010 1801 3 0.016 1509 2 0.010 0801 2 0.010
0204 1 0.005 3902 3 0.016 0704 2 0.010 1407 1 0.005
0224 1 0.005 3508 2 0.010 0401 1 0.005 1201 1 0.005
0205 1 0.005 4901 2 0.010 1302 1 0.005
6601 1 0.005 1401 2 0.010 1304 1 0.005
0102 1 0.005 1516 2 0.010 1502 1 0.005
2425 1 0.005 5301 2 0.010 0405 1 0.005
2301/05 1 0.005 3701 2 0.010 1102 1 0.005
4402 2 0.010 0809 1 0.005
2402/25 1 0.005 4501 2 0.010 1305 1 0.005
1302 2 0.010 1301 1 0.005
1517 2 0.010
3502 2 0.010
Other 20 0.107
N = 186.BMC Cancer 2009, 9:48 http://www.biomedcentral.com/1471-2407/9/48
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highly diverse and confirms the relevance of HLA-DR alle-
les in the genetic susceptibility to develop this specific
type of malignant disease.
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Table 4: Risk assessment among different loci of HLA class I
CASES N = 174 CONTROLS N = 186
Locus n g.f n g.f P OR C195%
HLA-A
0201 39 0.224 41 0.220 0.96 1.022 0.621–1.68
2402 25 0.143 31 0.166 0.648 0.839 0.473–1.48
0206 20 0.114 10 0.053 0.056 2.286 1.038–5.033*
3101 16 0.091 13 0.069 0.565 1.348 0.628–2.890
6801 8 0.045 19 0.102 0.068 0.424 0.180–0.995
HAL-B
1501 13 0.075 4 0.021 0.031 3.714 1.187–11.619+
3501 13 0.075 11 0.059 0.704 1.285 0.560–2.949
4002 11 0.063 13 0.069 0.966 0.898 0.391–2.062
5101 9 0.052 11 0.059 0.939 0.868 0.351–2.148
5201 9 0.052 4 0.021 0.21 2.482 0.750–8.211
HLA-Cw
0401 34 0.195 36 0.194 0.929 1.012 0.6–1.706
0702 29 0.167 40 0.215 0.302 0.73 0.430–1.241
0102 16 0.092 15 0.081 0.846 1.154 0.553–2.412
0701 13 0.075 9 0.048 0.411 1.588 0.661–3.814
0602 11 0.063 8 0.043 0.535 1.502 0.589–3.825
* Pc = 0.45. +Pc = 0.30.
Table 5: Risk assessment among different loci of HLA class II
CASES N = 174 CONTROLS N = 186
Locus n g.f n g.f P OR C195%
HLA-DRB1
0802 27 0.155 25 0.134 0.682 1.183 0.657–2.130
0407 22 0.126 33 0.177 0.231 0.671 0.374–1.204
1406 14 0.080 15 0.081 0.851 0.998 0.467–2.132
1301 7 0.040 1 0.005 0.06 7.754 0.944–63.689
1602 7 0.040 0 0 0.025 16.701 0.947–294.670*
HLA-DQB1
0302 79 0.454 51 0.274 0.0001 2.201 1.419–3.415**
0402 29 0.167 28 0.151 0.784 1.129 0.641–1988
0202 18 0.103 10 0.054 0.118 2.031 0.910–4.531
0301 4 0.022 43 0.231 0.00001 0.078 0.027–0.223***
0201 2 0.011 0 0 0.524 5.406 0.258–113.402
0303 1 0.005 2 0.011 0.954 0.532 0.048–5.918
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